Table Of Content

Journal of Pharmcokinetics and Biopharmaceutics, Vol. 19, No. 6, 1991 Author Index to Volume 19 Aarons, Leon, 265, 333, 485 Ganes, Derek A., 413 Alfrime, Melton B., 413 Garcia-Carbonell, M. Carmen, 647 Aizawa, Kazumasa, 597 Godfrey, Keith M., 227 Allerheiligen, Sandra R. B., lOlS Gonzalez-Younes, Iraida, 413 Antal, Edward, J., 9S, 37S, 93S Gonzalez, Rene, 385 Aristorena, Juan-Carlos, 647 Grasela, Jr., Thaddeus R., 9S, IIS, 87 Guedes, Jean-Paul, 271 Bailey, James M., 635 Gull, S. F., 497 Beal, Stuart, L., 319 Beck, James S., 473 Hale, Victoria G., 597 Benet, Leslie Z., 597 Hashimoto, Yukiya, 333 Bemareggi, Alberto, 21 Hartmann, Claudia, 385 Bloedow, Duane C., 385 He, Yan-Ling, 51, 667 Boddy, Alan V., 355, 373 Hetrick, David M., 1 Brouwer, Kim L. R., 189 Hori, Ryohei, 51, ^7 Brunden, Marshall N., 413 Hug, Jr., Carl C., 145 Bradwell, Arthur R., 227 Hunt, C. Anthony, 363 Buhrer, M., 377 Bunn, Jr., Paul A., 385 Jarabek, A. M., 1 Burk, Raymond F., lOlS Johnson, Tim K., 385 Jusko, William J., 521 Chapell, Michael J., 227 Charter, Michael K., 497 Kamiya, Akira, 51, 667 Cheng, Haiyimg, 521 Kasliwal, Ravindra, 385 Clementi, William A., 79S Kasuya, Yasuji, 113 Coldwell, James, 713 Kewitz, Helmut, 553 Crouet, William R., 271 Kitts, Jack, 713 Kurita, Masahiro, 469 Daley-Yates, Peter T., 175 Lajiness, Michael S., 457 Danhof, Meindert, 123, 485, 617 Lavene, Daniele, 287 Dienhart, David G., 385 Donati, Fran9ois, 537 Looby, Michael, 553 Ludden, Thomas M., lOlS Dubray, Claude, 287 MacGregor, Roderick, D., 363 Ebling, William F., 123 Maitre, Pierre O., 377 Ereshefsky, Larry, 93S Mandema, Jaap W., 485, 617 Evans, R. Lee, 93S Martin, III, Emory C., 59S Mason, William D., 157 Francheteau, Patrice, 287 Maiza, Amor, 175 Fu, Chauhwei J., 157 Marzo, Antonio, 473 Furuta, Takashi, 113 McQueen, E. G., 575 733 009(M«6X/9l/1200-0733S06.S0/0 © >991 Plenum Publishing Corporation 734 Author Index Meistelman, Gaude, S37 Shimota, Hirotaka, 113 Melethil, Srikumaran, 1S7 Siegel, Ronald A., 363 Midha, Kama! K., 413 Smith, Randall B., 37S, 93S Miller, Ronald D., 713 Stanski, Donald R., 123, 377 Modi, Nishit B., 40S Steimer, Jean-Louis, 287 Szlam, Fania, 145 Nakagawa, Tenimichi, 71 Nitz, Manfred, 553 Tanigawara, Yusuke, 51 Thomas, Gillian D., 227 Olson, Larry D., 413 Tomson, D. U., 337 Olson, Stephen C., 47S Torres-Molina, Francisca, 647 Toussaint, Susanne, 553 Patrick, James E., 413 Tozer, Thomas N., 271 Peris-Ribera, Jose-Esteban, 647 Travis, C. C., 1 Piortrovskii, Vladimir K., 311 Tung, Ying, 87 Pla-Delfina, Jose M., 647 Pollack, Gary M., 189 Veng-Pedersen, Peter, 405, 617 Purves, R. D., 575 Verotta, Davide, 319, 691, 713 Reigner, Bruno G., 271 Rescigno, Aldo, 473 Wagner, John G., 413 Wald, Jeffrey A., 521 Roberts, Michael S., 575 Walawander, Cynthia A., 87 Rodrigues, Rita, 713 Wanwimolruk, S., 575 Rowland, Malcolm, 1 Weber, Willi, 553 Wells, Barbara G., 93S Salazar, Daniel E., 521 Saito, Yoshihiro, 51 White, Donald B., 87 Sackellares, J. Chris, 413 Sambol, Nancy C., 79S Yagi, Betty H., 457 Schwieiger, Ian M., 145 Yamaoka, Kiyoshi, 71 Sheiner, Lewis B., IIS, 25S, 79S, 319, 333, Yano, Yoshitaka, 71 597, 691, 713 Yasui, Hiroyuki, 71 Shen, J., 575 Shibasaki, Hiromi, 113 Zurenko, Gary E., 457 Journal of Pharmacokinetics and Biopharmaceutics, Vol. 19, No. 6, 1991 Subject Index to Volume 19 Absorption, 413 Effect of buffer, 157 Absorption rate, 485 Electroencephalogram, 123 Amino-^-lactam absorption, 271 Elimination rate constant, 311 Anesthetics, 123, 145 Enflurane, 145 Antibodies, 227 Enterohepatic recirculation, 189 Approximation, 405 Experimental renal failure, 175 Arterial-venous concentration difference, 71 Extracorporeal, 385 Aspirin, 157 RLT, 71 Baye’s theorem, 497 Flunarizine, 413 Bias, 87 Flurbiprofen, 413 Biliary excretion, 189 Biphasic pharmacodynamic model, 123 Glomerulo-tubular imbalance, 175 Bioavailability, 497 Glucocortoid receptors, 521 Glucuronidation, 189 Calculation formula, 405 Cefatrizine, 271 Hepatic clearance, 598 Cell trafficking, 521 Hepatic extraction, 598 Cephalexin, 71 Hormone, 287 Cinetidine, 175 Circadian variation, 287 Identifiability, 227 Clinical trials, 87 Immunoadsorption, 385 Compartmental models, 227, 385, 413 Input rate, 497 Computer program, 405 Intact nephron hypothesis, 175 Colony forming units, 457 Interspecies scaling, 21 Confidence intervals, 87 Intravenous infusion, 21 Corticosteroids, 521 Intrinsic clearance, 598 Cyclosporin, 21 Ketamine, 145 DCN 203-922, 287 Kinetics, 145 Deconvolution, 485 Design, 333 Labetalol, 145 Disposition, 413 Laplace transfer, 71 Distribution study, 21 Linear pharmacokinetics, 405 Dopaminomimetic drug, 287 Linear systems, 355 Dose response, 333 Linear systems analysis, 319 Drug dosing, 405 Liver perfusion, 598 Drug intervals, 405 Local disposition, 71 Drug metabolism, 145 Drug targeting, 355 MAC, 145 Man, 21 EEC, 485 Maximum entropy, 485 735 009(M66X/91/I200-073SS06.SO/0 © 1991 Plenum Publnhing Corpontioa 736 Subject Index Mean residence time, SI Population analysis, 333, 337 Mesoirdazine, 413 Population pharmacokinetics, 87 Metabolite formation, SS3 Postantibiotic effect, 457 Metabolite kinetics, 311 Predisolone, 598 Methylchloride, 1 Prednisone, 598 Methylchloroform, 1 Probenecid, 51 Methylpredisolone, 521 Prolactin, 287 Metroprolol, 71 Protein binding, 575 Michaelis-Menten equation, 271 Pulmonary elimination, 71 Michaelis-Menten parameters, 1 Midazolam, 48S Rats, 21, 157 Midazolam pharmacokinetics, 377 Reabsorption, 189 Modeling, 521, 537, 557 Recirculation, 145 Model structure-independent assessment, 311 Recirculation model, 355 Moment analysis, 51 Recirculation pharmacokinetics, 51 Monoclonal antibody, 385 Recirculatory, 71 Monoexponential model, 87 Recirculatory modeling, 363 Monte Carlo, 1 Regional delivery, 363 Multicompartment systems, 485 Renal clearance, 175 Renal excretion, 51 N-1-methylnicotinamide, 553 Residence times, 319 Neuromuscular blocking drugs, 537 RIA, 21 Nicotinic acid metabolite, 553 Nonlinear models, 227 Salicylate pharmacokinetics, 553 NONMEM, 87, 485 Saturable absorption, 271 Saturation of tubular reabsorption, 553 Sensitivity, 1 Onset time, 537 Simulation, 385 Optimal dosing, 405 Simulations, 87, 287 Organic cation, 553 Simulations of absorption models, 271 Organs blood content, 21 Spline smoothing, 287 Osmotic pumps, 21 Standard error; 87 Steady state, 405 p-aminohippurate, 51 Stochastic modeling, 363 p-aminohippuric acid, 175 Styrene, 1 Parallel-tube model, 598 System analysis, 553 Pharmacodynamics, 497, 537 Pharmacokinetics, 157, 355, 385, 537, 553 Targeting, 363 Pharmacokinetic models, 1 Thiopental, 123 Pharmacokinetics/pharmacodynamic model, Transepithelial transport, 51 287 Tubular secretion, 21, 553 Pharmacokinetics/pharmacodynamic model¬ Tumor targeting, 227 ing, 485 Two-phase regression, 457 Pharmacokinetics/pharmacodynamics, 333 Type of renal disease, 175 Physiologic flow models, 319 Physiologic modeling, 363 Valproic acid, 189 Physiologic pharmacokinetic model, 21 Placebo, 287 Well-stirred model, 598